Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Arteris, Inc. (Nasdaq: AIP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Arteris describes itself as a global leader in system IP used in semiconductors, and its filings offer formal detail on the financial and operational aspects behind that business.
Among the key documents are current reports on Form 8-K, which Arteris uses to furnish press releases announcing quarterly financial results and other material events. For example, the company has filed 8-Ks referencing press releases on results for quarters ended June 30 and September 30, including metrics such as revenue, licensing and royalty performance, operating loss, and Remaining Performance Obligations. These filings give investors structured insight into how Arteris’ licensing, support and maintenance, and variable royalty revenue streams are evolving.
Users can also review other periodic reports, such as Forms 10-Q and 10-K when available, to understand topics like segment performance, risk factors, and detailed financial statements that complement the high-level figures cited in press releases. For those interested in governance and ownership, SEC filings are the place where proxy statements and beneficial ownership reports would appear.
Stock Titan enhances this information by pairing real-time updates from EDGAR with AI-powered summaries that highlight the main points of lengthy filings. Instead of reading every line of a multi-page 10-K or 10-Q, users can rely on AI explanations to quickly identify revenue trends, key risks, and notable changes. The platform also surfaces insider transaction reports on Form 4 when filed, helping investors monitor trading activity by Arteris officers and directors.
By using this page, investors and researchers can efficiently navigate Arteris’ official SEC disclosures, from earnings-related 8-Ks to comprehensive annual and quarterly reports, supported by AI tools that make complex documents easier to interpret.
Arteris, Inc. has filed a shelf registration statement covering the resale of up to 985,675 shares of common stock by selling stockholders who received these shares in the Cycuity, Inc. acquisition. The company will not receive any proceeds from these secondary sales.
The selling stockholders may dispose of their shares from time to time using various methods, including brokered and underwritten transactions, as described in the plan of distribution. As context, there were 45,467,261 shares of Arteris common stock outstanding as of February 5, 2026.
Arteris, Inc. reports 2025 results showing continued growth but ongoing losses as it invests heavily in semiconductor system IP. Revenue for the year ended December 31, 2025 was $70.6 million, up from $57.7 million in 2024, driven by demand for its network‑on‑chip and SoC integration automation products across automotive, AI, communications, aerospace and other markets.
The company remains unprofitable, with a net loss of $34.7 million in 2025 versus $33.6 million in 2024, reflecting high R&D spending of $49.9 million, or 71% of revenue. Operating cash flow improved to $6.7 million provided in 2025 after using $0.7 million in 2024, signaling better cash discipline despite losses.
Arteris highlights Annual Contract Value of $77.0 million and ACV plus royalties of $83.6 million as of December 31, 2025, indicating a growing recurring revenue base. Management emphasizes leadership in system IP for complex SoCs, expansion into security verification via the Cycuity acquisition, and exposure to fast‑growing AI, automotive and multi‑die chip markets, while warning of intense competition, customer concentration, international and regulatory risks, and the possibility of continued net losses.
Arteris, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining unprofitable. Q4 revenue reached $20.1 million, up 30% year over year, with Annual Contract Value plus royalties at a record $83.6 million, up 28%.
Remaining performance obligations were $116.8 million, up 32%, and Q4 non-GAAP free cash flow was positive $3.0 million. For 2025, revenue was $70.6 million, up 22%, but GAAP net loss was $34.7 million. 2026 guidance calls for revenue of $89.0–$93.0 million and non-GAAP operating loss of $5.0–$9.0 million.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc., reported open-market sales of the company’s common stock under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2025.
The LLC sold 47,244 shares on February 9, 2026 at a weighted average price of $15.2053 per share and 2,756 shares on February 10, 2026 at a weighted average price of $15.0322 per share. After these transactions, it indirectly held 9,349,071 Arteris shares, with voting and dispositive power deemed to be held by manager K. Charles Janac.
Arteris, Inc. reported insider share sales by an entity managed by its President and CEO, Charles K. Janac. Bayview Legacy, LLC, over which he has voting and dispositive power, sold 47,244 shares of common stock on February 9, 2026 at a weighted average price of $15.2053 per share and 2,756 shares on February 10, 2026 at a weighted average price of $15.0322 per share. These sales were made under a Rule 10b5-1 trading plan adopted on March 5, 2025. After these transactions, Bayview Legacy, LLC held 9,349,071 shares indirectly for Janac. He also held 139,487 shares directly and 56,252 shares indirectly through the Charles and Lydia Janac Trust, where he serves as trustee.
Arteris, Inc. VP and General Counsel Paul L. Alpern reported an automatic option exercise and share sale in Arteris, Inc. common stock. On February 2, 2026, he exercised options for 5,000 shares at an exercise price of $0.56 per share and then sold 5,000 shares of common stock at a weighted average price of $15.4753 per share.
The transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted on June 5, 2025. Following these transactions, Alpern beneficially owned 57,650 shares of Arteris common stock directly, and 65,000 derivative securities (stock options) remained outstanding with an exercise price of $0.56 per share, expiring on October 23, 2029.
Arteris, Inc. insider activity: An entity associated with President and CEO Charles Janac reported a planned sale of company stock. On January 15, 2026, Bayview Legacy, LLC sold 17,884 shares of Arteris common stock at a weighted average price of $17.8357 per share, under a Rule 10b5-1 trading plan adopted on March 5, 2025. Following this sale, Bayview Legacy, LLC held 9,399,071 shares beneficially owned, over which Janac, as manager, is deemed to have voting and dispositive power.
Separately, Janac held 139,487 shares directly and 56,252 shares indirectly through the Charles and Lydia Janac Trust, where he serves as trustee.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc. (AIP), reported selling 17,884 shares of Arteris common stock on
Following this sale, Bayview Legacy, LLC reported beneficial ownership of 9,399,071 Arteris shares held indirectly. K. Charles Janac is the manager of Bayview Legacy, LLC and is deemed to have voting and dispositive power over these shares, and he has separately filed his own Form 4 for the same transaction.
Arteris, Inc. insider activity shows a small planned share sale by an entity managed by its President and CEO, Charles K. Janac. On 01/13/2026, Bayview Legacy, LLC, over which Janac has voting and dispositive power, sold 2,116 shares of Arteris common stock at a weighted average price of $17.7901 per share under a Rule 10b5-1 trading plan adopted on March 5, 2025. Following this transaction, Bayview Legacy, LLC held 9,416,955 shares indirectly for Janac, while he also held 139,487 shares directly and 56,252 shares indirectly through the Charles and Lydia Janac Trust, where he serves as trustee.
Bayview Legacy, LLC, a 10% owner of Arteris, Inc. (AIP), reported an open-market sale of 2,116 shares of Arteris common stock on January 13, 2026. The shares were sold at a weighted average price of $17.7901 per share, in multiple trades between $17.7500 and $17.8100. The transaction was made under a Rule 10b5-1 trading plan adopted on March 5, 2025, meaning the sales followed a pre-set schedule. After this sale, Bayview Legacy, LLC indirectly beneficially owned 9,416,955 shares, and its manager, K. Charles Janac, is deemed to have voting and dispositive power over those shares.
FAQ
What is the current stock price of Arteris (AIP)?
What is the market cap of Arteris (AIP)?
